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A striking common feature of many autoimmune diseases in humans and experimental animals,
despite differences in pathology, is that females are highly susceptible to autoimmune conditions
compared to males. In several animal models, estrogens promote, whereas androgens abrogate,
B-cell-mediated autoimmune diseases. To understand mechanisms by which estrogens regulate
autoimmunity, it is first necessary to decipher estrogen effects on the normal immune system.
Estrogen treatment of nonautoimmune mice diminished lymphocyte numbers in both
developmental and mature lymphoid organs. Estrogen dysregulated T- and B-cell balance by
inducing selective T-cell hypoactivity and B-cell hyperactivity. Even though estrogen did not alter the
relative percentages of splenic T-cell subsets, splenic lymphocytes had a reduced proliferative
response to T-cell stimulants and were refractory to rescue from activation-induced apoptosis
compared to cells from placebo-treated mice. In contrast, estrogen induced B-cell hyperactivity
(promoted autoantibodies to double-stranded DNA and phospholipids, increased numbers of plasma
cells, and increased autoantibody yield per B cell). Note that treatment of normal mice with
estrogen can alter T- and B-cell regulation and overcome B-cell tolerance to result in autoimmunity
in normal individuals. Could environmental estrogens promote some human autoimmune
disorders? Is there a link between environmental estrogens and autoimmune disorders, especially
since these disorders are reported possibly more frequently? These provocative questions warrant
investigation. Our findings on immunomodulatory effects may serve as a benchmark to examine
whether endocrine-disrupting chemicals will have similar immunologic effects. Key words:
autoantibodies, autoimmune diseases, autoreactive cells, B cells, diethylstilbestrol, endocrine-
disrupting chemicals, estrogens, T cells. - Environ Health Perspect 107(suppl 5):681-686 (1999).
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It is evident that there are marked or subtle
gender differences in the functioning ofsev-
eral nonreproductive tissues. There are thou-
sands of research manuscripts that have
pointed out gender differences in various
tissues and systems, including the immune
system. The immune system serves as
an archetypal example ofgender differences
in nonreproductive sites (see "Gender
Differences in Immune Responses"). Given
the marked impact ofgender on tissue physi-
ology, it is imperative to include gender as a
variable in clinical and experimental studies.
Nevertheless, many research protocols do not
include study subjects ofboth genders nor do
theystrictly control forgender (unlike impor-
tance given to age or strain), an aspect that
warrants attention.
Females as agender group haveheightened
immune responses not only to foreign anti-
gens but also to self-antigens [reviewed in
(1-6)]. Thus, there is a greater preponder-
ance of autoimmune disorders in women
than in men [see "Gender Differences in
Immune Responses"; also reviewed in
(1-5,7)]. It is important to recognize that
autoimmune diseases can afflict almost any
tissue, akin to cancer. Conceivably, the initi-
ating and pathogenic mechanisms are most
likely to be different in various types of
autoimmune diseases. Yet, in general, women
are more susceptible than men to autoim-
mune diseases. Therefore, gender is a com-
mon thread that stitches together the
disparate autoimmune conditions.
Gender Differences in Immune
Responses
In general, females as a gender group have
better B-cell-mediated immunity (often, per-
haps incorrectly, referred to as humoral
immunity) than age-matched male counter-
parts [reviewed in (1-6)]. They have higher
immunoglobulin levels, stronger antibody
responses to various foreign antigens, and
increased resistance to certain infections
[reviewed in (1-6)]. Gender differences in
T-cell-mediated immunity also exist,
although the gender influences appear to be
complex [reviewed in (1-6,8)]. Females have
greater resistance to induced tolerance,
increased ability to reject grafts, and increased
CD4 to CD8 ratios. Also, females tend to
secrete higher levels of interleukin (IL)-4,
interferon-y (INF-~y), and IL-1. Sex hormonal
action on the immune system is thought to
account for gender differences in immune
capability, dispelling the notion that sex
steroid hormones exclusively affect sex-
related endocrinologic functions.
Sources of Exposure to
Estrogens: Natural, Synthetic,
and Environmental Estrogens
In addition to natural estrogens, human and
animals are exposed to estrogens in different
forms. The exposure to synthetic and envi-
ronmental estrogens is believed to have
increased over the years. Diethylstilbestrol
(DES), a potent synthetic estrogen, has been
used as a therapeutic agent in a variety of
clinical situations including threatened abor-
tions, preeclampsia, prior premature labor,
prostatic and breast cancer, pregnancy com-
plications in diabetic women, and whenever
estrogen-replacement therapy was indicated
(9-11). Although DES is no longer used dur-
ing pregnancy, it is estimated that 2-4.8 mil-
lion human offspring were exposed to DES
from the 1940s through 1971 (12). Human
exposure to DES is suspected to have also
occurred through consumption of meat and
milk products oflivestock that were fed DES
as a food additive. Moreover, there was an
occupational exposure to farmers handling
DES (13). Estrogens are now increasingly
prescribed for postmenopausal women for
prevention of bone loss and cardiac myo-
pathies. Further, a greater number of women
worldwide are on prolonged estrogen-based
oral contraceptives. Finally, an increasing num-
ber ofpeople are unintentionally exposed to a
wide range ofsynthetic chemicals such as pesti-
cides, industrial byproducts, insecticides,
fungicides, and herbicides that have estrogenic
or antiestrogenic effects (13-15). Food ani-
mals are likely to have been exposed to estro-
genic zearalanol and/or zearalenone, an
estrogenic Fusarium-derived mycotoxin in
contaminated diet. It is likely that a subset of
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thepopulation that maybeexquisitelysensitive
to estrogenic compounds maybe at riskfor the
developmentofautoimmunediseases.
Gender Difference in
Autoimmune Diseases: The
Role ofEstrogenic Compounds
Human Studies
Genetic, viral, stress, and sex hormonal factors
all play a complex role in the etiology of
autoimmune diseases. For the first three of
these four factors, despite intense research
activity and exciting new data, their precise
contribution to autoimmune disease is not
yet clear. For sex hormones, however, the
clinical observations that autoimmune dis-
eases occur more frequently in females com-
pared to males offers exciting new avenues of
research to better understand the promotion,
progression, and possible treatment of
autoimmune diseases. We and others have
extensively documented gender differences in
the expression ofautoimmune diseases in pre-
vious reviews (1-5,7). A partial list offemale
predominance of autoimmune diseases is
shown in Table 1. [See Ansar Ahmed et al.
(1) for a more detailed list ofgender differ-
ences.] A recent epidemiologic study on the
prevalence of24 autoimmune diseases esti-
mated that 1 in 31 Americans (almost 9 mil-
lion), mostly women, are afflicted with some
type ofautoimmune disease (16). Of the
autoimmune diseases studied, thyroid
autoimmune disorders, rheumatoid arthritis,
insulin-dependent diabetes, and pernicious
anemiawere common autoimmune disorders.
Most ofthese disorders predominantly afflict
women. Although individual autoimmune dis-
ease may be relatively uncommon, collectively
theyconstitute asignificant concern to internal
medicine. Autoimmune diseases are believed
to be more frequently reported, which may
be due to better recognition ofthese diseases
by physicians and patients, coupled with
more sensitive diagnostic procedures.
Nevertheless, the possibility that there is a
true increase in autoimmune disease cannot
be completely discounted. Could the possible
increase in the incidence ofautoimmune dis-
eases be due to exposure to environmental
estrogens? This provocative question needs to
be answered in future studies, especially with
regard to the impact ofendocrine-disrupting
chemicals on disease initiation orprogression.
The influence ofsex hormones on human
autoimmune diseases is evidenced by the
observation that the course ofmany ofthese
disorders is modulated during the periods of
sex hormonal alterations (e.g., pregnancy,
administration of oral contraceptives, or
menopause) [reviewed in (1-5,7)]. Limited
data in humans have shown that dehydro-
epiandrosterone therapy in systemic lupus
erythematosus (SLE) patients (17) or andro-
gen replacement therapy in a Klinefelter syn-
drome patient with SLE (18) had apparent
beneficial effects.
Women prenatally exposed to DES are
susceptible to the development ofadenocar-
cinomas ofthe cervix and vagina (9-12,19)
and reproductive abnormalities [vaginal
adenosis and infertility (9,12)]. Further, a
link between prenatal DES exposure and
autoimmune disease has been suggested
(20,21). Women prenatally exposed to DES
appear to have a higher incidence of auto-
immune diseases but only when various
autoimmune disorders are grouped (20,21).
Women with vaginal epithelial changes had
nearly 50% more autoimmune diseases
than DES-exposed women lacking these
Table 1. A partial list ofgender differences in human and experimental autoimmune disease.
Human Animal models
Female to Female to
Autoimmune disease male ratio Autoimmune disease male ratio
Autoimmune thyroiditis Autoimmune thyroiditis
Hashimotothyroiditis 25:1 Spontaneous (BUFrats) 3:1
Graves-Basedow disease 4 to 8:1 Induced
Thymectomy-irradiation 4 to 6:1
Neonatal thymectomy 4:1
Chemical and autoantigen 2:1
SLE 9to 13:1 SLE Earlierexpression of
Sjogren syndrome 9:1 Rheumatoid arthritis and/or autoimmune disease
Sjogren syndrome orautoantibodies in
females, e.g.,
(NZB x NZW)F1, SNFl,
(NZB x DBA/2)Fb,
(NZB x DBA)F1,
Rheumatoid arthritis 2:1 MRL/lpr/lpr
Juvenile onsetofmyasthenia gravis
(White patients) 2 to 14:1
(Black patients) 1:1 (approx)
Scleroderma 3 to 4:1 Polyarthritis (LEW rats) 6:1
SLE, systemic lupus erythematosus. Modified from AnsarAhmed et al.(1).
pathologic changes (20). The DES-adenosis
report (20) stated
The information presented in this pre-
liminary communication also supports the
concept that human exposure before birth
to DES may subsequently affect the adult
immune system. Additional studies should
be undertaken to thoroughly investigate
the function of the immune system in
DES-exposed women by means ofappro-
priateserologic testing.
An epidemiologic questionnaire-based
study involving 1,700 respondents (including
mothers, daughters, sons) revealed that respi-
ratory infections (flu, colds), asthma, arthritis,
and lupus were reported more frequently
(21). This suggests that prenatal DES expo-
sure contributed to immune impairment.
Another recent but smaller preliminary study
involving self-reported cases ofallergy, infec-
tions, and autoimmune diseases did not find
an association ofthese disorderswith prenatal
DES exposure (22). Nevertheless, these
authors felt further studies are needed to con-
clusively establish the link between prenatal
DES exposure and autoimmune diseases.
Large double-blind human studies are needed
to address this aspect.
AnimalStudes
Akin to the human situation, gender differ-
ences in autoimmune diseases and/or sex hor-
monal influences on the expression ofthese
disorders are evident in many animal models
ofautoimmune diseases [Table 1;(1-5)].
Space restrictions do not permit comprehen-
sive discussion ofliterature and therefore only
selected recent information is induded here. A
relatively new murine model for SLE has been
described in female (SWR x SJL)F1 mice.
These micehave increasedhypergammaglobu-
linemia, a 2-fold increase in spleen cell num-
bers, and make anti-Sm/UlsnRNP antibodies
(which react with autogenic peptides), com-
pared to males. IgG antibodies react with
PPPGMRPP, an octapeptide thought to be a
strong immunoreactive linear epitope in SLE
patients with anti-Sm/UlsnRNP antibodies
(23). The increased susceptibility offemale
(SWR x SJL)F1 mice to lupus resembles the
differential sex susceptibility in (NZB x
NZW)F1, or B/W, and (NZB x SWR)F1, or
SNF1, mice. In B/W mice, depletion ofmale
hormones (by administration ofestrogens or
antiandrogens to orchiectomized males) accel-
erates the manifestation ofthe disease (1-5,
24,25). Conversely, female BIW mice can be
made resistant to thediseasebyadministration
ofandrogens or antiestrogens (1-5,24). In
SNFI mice, resistant males were rendered sus-
ceptible by estradiol or 2,3,7,8-tetrachloro-
dibenzo-p-dioxin (2,3,7,8-TCDD) treatment
(26). Estrogen-induced exacerbation of
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autoimmune disease is thought to be mediated
through alterations in T cells (increased CD4+
cells in the thymus and CD4+ memoryT cells
in thespleen andkidneys) (26). Estrogen pro-
motion ofautoimmune disease has also been
shown in MRL/lpr/lpr mice, (which develop
an aggressive disease with lymphadenopathy)
(27), and in an immunized model for SLE
(16/6 idiotype bearing anti-DNA antibodies)
(28). In the nonobese diabetic strain of
mouse, the incidence ofspontaneous diabetes
is increased in females compared to males.
The susceptibility ofmales is augmented by
orchiectomy (29). Orchiectomy combined
with thymectomy considerably enhances the
incidence ofthe disease, suggesting that male
hormones may act via the gonadal-thymic
axis. In a mouse model of arthritis, female
mice have a greater ability to degrade
implanted cartilage than males (30).
Granulomata from female mice had higher
levels of IL-1, implying that sex hormone
modulation ofcartilage destruction may be
mediated by cytokines. In experimental
autoimmune encephalomyelitis in SJL mice
injected with myelin basic protein-specific T
cells, dihydrotestostrone was effective in
diminishing the severity ofthe disease (31).
The protective effects apparently are related to
enhanced production of IL-10 by antigen-
specificTlymphocytes.
Mice given DES during the perinatal
(neonatal) period have an impaired immune
system (particularly T cells), including atrophy
ofthe thymus, reduced proliferative response
toT-cell mitogens, diminished antigen-specific
delayed-type hypersensitivity response and
graft versus host reaction, decreased cytotoxic
response to mammary tumor virus, and
decreased natural killer cell function (32-36).
Therefore, concerns have been raised that the
exposure offetuses to estrogenic compounds
during the highly critical stage of immune
development may alter the immune system.
We are currently investigating the immune
consequences ofprenatal exposure to DES in a
murine model. These studies may also be rele-
vant to other endocrine-disrupting chemicals
(e.g., octylphenol orgenestein).
The following section describes studies
from our laboratory as well as others on the
immune effects ofestrogen in normal ani-
mals. Extensive studies in our laboratory have
identified immune cells that are modulated
byestrogen.
Immune Biomarkersfor
Estrogenic Compounds
Effects onThymusandTCells
To better understand how sex hormones
regulate autoimmune responses and to iden-
tify the target organs and cells, it is essential
to first decipher their effects on normal
immune systems, an aspect thus far not well
understood. Toward this aim, we gave estro-
gen (171-estradiol in silastic capsules) to pre-
pubertal orchiectomized normal C57BL/6
mice and examined their splenic and thymic
tissues after 3-6 months (37-40). Extensive
studies from our laboratory as well as others
have established immune biomarkers for
estrogen [Table 2; (37-41)]. These parame-
ters may be useful in ascertaining the
immunologic consequences ofexposure to
endocrine disrupters. Chronic estrogen treat-
ment diminished lymphocyte numbers in
both developmental (thymus, bone marrow)
and mature (spleen, lymph nodes) lymphoid
organs. Estrogens (presumably including
DES) induced atrophy of the thymus.
Estrogen also altered intrathymic T-cell sub-
sets (e.g., loss ofCD4+8+ thymocytes) (Figure
1). To address whether estrogenic com-
pound-induced atrophy ofthe thymus is due
to direct induction ofapoptosis ofthymo-
cytes, normal thymocytes were cultured with
various doses of DES and the kinetics of
apoptosis was determined. Parallel cultures of
thymocytes were exposed to a known thymic
atrophy- and thymocyte apoptosis-inducing
hormone, dexamethasone (DEX). Apoptosis
was evaluated byflowcytometric examination
ofcells stainedwith propidium iodide (PI), 7-
aminoactinomycin D (7-AAD), or fluorescein
isothiocyanate-annexin V; by forward/side
scatter analysis, cell-size analyzer, and
cytopathologic examination. In our extensive
studies, apoptosis could only be detected in
thymocyte cultures exposed to DEX but not
in those exposed to DES (41). These studies
imply that these two synthetic hormones
induce atrophy ofthe thymus by dissimilar
mechanisms in vivo. A recent study using
transgenic mice overexpressing antiapoptotic
oncogene bcl-2has shown that administration
of 171B-estradiol, but not DEX, can induce
thymic atrophy, thereby suggesting that these
two hormones have different modes ofaction
(42). Alternatively, thymic injury mediated by
Table2. Immune biomarkers for estrogen.
Hyperactivity of B cells
T Immunoglobulins and autoantibodies
1 Number ofplasma cells
1 Output of autoantibodies per B cell
1 Number of cells in the S phase ofcell cycle
1 Survival of activation-induced apoptosis
Impairment ofT-cell function
1- Proliferative response to T-cell stimulants
Unresponsive to activation signals for rescue from
apoptosis
J CD69 expression afterT-cell stimulation
T IFN-yatprotein and mRNA levels
Dampened NK cell activity
Increased granulocytes
1 Ly6G+(Gr-1)
Abbreviations: IFN-j, interferon-y; NK, natural killer.
estrogen or DES may be due to diminished
immigration of prothymocytes from the
bone marrow or hormonal effects on thymic
stromal cells (possibly by altering their secre-
tion ofcrucial cytokines such as IL-1, IL-6, or
IL-7, or by inducing apoptosis ofthese cells).
Sex steroid receptors have been demon-
strated on thymic epithelial/stromal cells,
possibly on thymocytes, and on peripheral
T-cell subsets in a number of species
[reviewed in (1-6)]. A putative model sug-
gests that sex steroid hormones bind to intra-
cellular receptors (nuclear or possibly in the
cytosol) in lymphocytes; this complex binds
to sex steroid hormone-responsive elements
in the DNA to modify cellular activity. Sex
hormones induce the thymus to release im-
munoregulatory thymic factors that can also
act on the hypothalamus-pituitary axis to
release other immunoregulatory peptides
[reviewed in (1-6)]. Studies also suggest
that developing thymus and T cells are
direct or indirect targets for estrogenic com-
pounds. Induction ofa hyperestrogenic state
induced by estrogen treatment ofpregnant
guinea pigs or DES injections ofpregnant
mice resulted in reduction in the number of
large cortical cells ofthe fetal guinea pig thy-
mus (43) and lowered response to T-cell
mitogens (27). Our ongoing studies show
that nonautoimmune mice prenatally exposed
to DES have altered thymocyte numbers or
functions (44). Thus, it is conceivable that
exposure to estrogenic compounds during
fetal life could be a potential immunologic
Thymus
Estrogen
CO E
EU1 CD1
Thymic weights Thymic cell numbers
1251
~ ~~~~ t100
_~~ ~~~~ 7 -51
'2 m-
mm
'
CU 2
Placebo Estogen Placebo Estogen
ICD4184(immature)thymocytes
1 CD41(mature)thymocytes
J CD69(very eadyactivation surfacemarker)
afterPMAV+ionomycinstimulation
Figure 1. Estrogen effects on thymus. Normal orchiec-
tomized C57BL/6 mice were given estrogen or sham
treatment (as a subcutaneous implants of silastic cap-
sules for 3-6 months). Thymuses ofthese mice were iso-
lated and weighed, and thymocytes were enumerated.
Thymocytes were stained with phycoerythrin-anti-CD4
and fluorescein isothiocyanate-anti-CD8 antibodies to
determine relative numbers of single-positive (CD4+ or
CD8+) and double-positive (CD4+CD8+) cells by flow
cytometry. In some studies thymocytes were stimulated
with phorbol 12-myristate 13-acetate (PMA) plus iono-
mycin and 8-9 hr later the cell surface expression of
CD69 determined. Bar indicates standard error.
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hazard. Concanavalin A (ConA)-stimulated T
cells from estrogen-treated mice have an early
defect, as they have decreased expression of
CD69 and have decreased ornithine decar-
boxylase activity (an early enzyme in polyamine
biosynthesis) compared to that in controls.
Sex hormones can affect autoimmune
diseases by modulating the activity ofCD4+
helper cells. The effects ofestrogen on CD4+
cells are best depicted in studies on I2-
microglobulin-deficient mice infected with
lymphocytic choriomeningitis virus. Females
were more susceptible to fatal CD4-mediated
meningitis compared to males (45). Estrogen
treatment oforchiectomized mice rendered
these males susceptible to meningitis. In vitro
studies confirmed that CD4-mediated cyto-
toxicitywas dependent upon estrogen.
Sex hormones could affect the type or
levels ofT-cell-derived cytokines. In our
studies on estrogen-treated normal C57BL/6
mice, splenic lymphocytes stimulated with
T-cell stimulants had increased IFN-,ymRNA
as well as IFN-y protein (46). Addition of
estrogen to CD4+ T-cell lines from multiple
sclerosis patients resulted in increased produc-
tion ofIL-10 and IFN-y (47). Sex hormones
could have differential effects on lymphocytes
from autoimmune patients compared to
those ofcontrols, as was noticed in IL-1 and
IL-6 production in lymphocytes from healthy
and rheumatoid arthritis patients, which were
cultured with estrogen (48). Similarly, it is
plausible that endocrine disruptors could
have differential effects on normal and
autoimmune individuals, an aspect currently
investigated in our laboratory. Further
evidence for sex hormonal effects on
T-cell-derived cytokines is evident in studies
where culturing of antigen-specific CD4+
T-cell lines in the presence ofprogesterone
resulted in a shift from T-helper (Th)1 to
ThO or Th2-type cytokine profiles (49).
Further, when known Thi cellswere cultured
in the presence ofprogesterone, there was a
transient synthesis of IL-4 and transient
expression ofCD30, which are characteristics
ofTh2 cells (49). Receptors for progesterone
in lymphocytes appear to be selectively
increased during pregnancy or mitogenic
stimulation (50). Other studies have shown
that lymphocytes cultured in the presence of
progesterone produce an immunomodulatory
protein that selectively induces IL-10, IL-4,
and IL-3 production by ConA-stimulated
lymphocytes (51). Th2-type cytokines
secreted by placental tissues are thought to
play an important role in maintenance of
pregnancy. Is the pregnancy loss noticed in
SLE patients (who manifest altered levels or
metabolism ofsex hormones) due to shifts in
the hormone-induced cytokine balance (pos-
sibly to ThI type)? This challenging question
warrants furtherstudies.
EstrgnicCompounds, B-Cell
Hyperacivity, andAutoantibodies
Since estrogen drastically reduces the size of
the bone marrow cavity and the bone marrow
cellularity (and thymus), organswhere deletion
ofautoreactive cells occur, it is likely that lym-
phocytes such as B cells may develop in alter-
native sites where there is less stringent
selection (Figure 2). We thus envisioned the
possible appearance ofautoreactive cells in the
peripheral tissues (e.g., spleen) and expression
ofautoantibodies in the serum ofestrogen-
treated mice. We observed that estrogen-
treated mice have extensive hemopoietic
centers in the liver and spleen (40). Estrogen
treatment ofMRL/lpr/lpr mice resulted in the
appearance offorbidden clones in the liver
(52). These cells include al3TCRIntermediate,
Vj3+, orV,8+ T cells that often are deleted in
the thymus. Ourstudies show, byELIspot and
image cytometry, that estrogen activates B cells
to produce higher numbers of not only
immunoglobulin-producing cells but also
autoantibody-producing cells in the spleen
which were directed against double-stranded
DNA (dsDNA), cardiolipin, phosphatidylser-
ine, and actin (53). The number ofplasma
cells was significantly increased in the spleens
ofestrogen-treated mice, suggesting B-cell
hyperactivity. Further, sera ofestrogen-treated
normal C57BL/6 mice had IgM and IgG (pre-
dominantly IgG2b) autoantibodies against
dsDNA (39), cardiolipin, phosphatidylserine,
and phosphatidylinositol (37-39). Although
the pathogenic significance ofthese estrogen-
induced autoantibodies is not yet determined,
these studies may be important, as anti-
dsDNA antibodies are often seen in patients
with SLE and antiphospholipid antibodies are
present in antiphospholipid syndrome and a
subset ofSLE patients. Ourfindings show that
treatment ofnormal mice solely with estrogen
can override B-cell tolerance and promote
autoimmunity. It is likely that endocrine-
disrupting chemicals can also similarly pro-
mote B-cell hyperactivity. Our recent
preliminary data on mice prenatally exposed
to DES also suggest that B cells are modulated
by these estrogenic compounds. It is not clear
how estrogens (and, by analogy, environmen-
tal estrogens) promote B-cell hyperactivity.
Conjectural possibilities indude a direct effect
on the immune systemoran indirecteffectvia
the hypothalamic-pituitary axis. It is likely
that estrogen may act on T cells to elaborate
cytokines (e.g., Th2 cytokines), which in turn
promote the function ofB cells. Estrogen may
downregulate natural killer cells orT-suppres-
sor cells that regulate B-cell functions. B cells
from estrogen-treated mice may be readily
activated by autoantigens (which may be
available following increased hormone-
promoted cell death).
Although not conclusively proven,
infectious agents in the environment have
long been suspected to play a role in theonset
or progression ofautoimmune diseases. It is
thus conceivable that estrogen and possibly
environmental estrogens could activate a
latent infection that in turn could influence
the onset orcourse ofautoimmune diseases.
EstrognicChemicalsandApoptosis
Estrogenic compounds can conceivably affect
the immune and autoimmune responses by
directly or indirectly regulating the apoptotic
patterns oflymphocytes. This should not be
surprising considering that related steroid hor-
mones such as glucocorticoids directly affect
apoptosis ofthymocytes. Further, estrogenic
hormones affect apoptosis ofnonlymphoid
cells. For example, depletion ofestrogen can
deletio - it -l a -sils
Thymus Bone marrow
Emog m . '~~cmpud
Atrophy
Afuawucdy#neIIs
i Iev rigenratbymi/
bonemant erpcs
*Aberranlt perzjiphrs th3an.ce
Spleen
Letrogeac
Figure 2. Estrogen-induced alterations in lymphoid
organs. Estrogen induces marked atrophy of the thymus
and bone marrow. These two primary lymphoid organs
are principally involved in deletion of autoreactive cells.
Because estrogen profoundly affects these two vital
lymphoid organs, it is hypothesized that there may be
abnormal regulation of the peripheral tolerance and/or
development in extrathymic/bone marrow organs (e.g.,
liver), where the selection and deletion mechanisms
may be less stringent. These events may lead to the
appearance of autoreactive cells in the peripheral Iym-
phoid tissues (e.g., spleen).
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induce apoptosis in the uterine epithelium
(54) In breast tissue, however, estrogen is
thought to contribute to the pathology by
promoting the survival of estrogen-respon-
sive cancer cells, which is related to bcl-2
mRNA and protein expression (55). Recent
studies in our laboratory suggest estrogen
also modulates the apoptosis oflymphocytes
(40,56). By several methods, including flow
cytometric analysis ofcells stained with PI,
7-AAD, and Annexin, we find that spleens
from estrogen-treated mice have increased
numbers of apoptotic splenic lymphocytes.
We are currently investigating whether lym-
phocytes from estrogen-treated mice have an
altered expression of Bcl-2 or fas proto-
oncogenes. Splenic lymphocytes from
placebo-treated but not from estrogen-
treated mice, when activated with T-cell
stimulants (e.g., anti-CD3 antibodies) were
rescued from apoptosis. Lymphocytes
exposed to B-cell stimulants were resistant to
cell death (57). We also find that lympho-
cytes from mice prenatally exposed to DES
have altered apoptosis in response to certain
stimulants (58). There is evidence ofapopto-
sis and autoimmune diseases in patients with
Sjogren syndrome. There is an excessive and
inappropriate apoptosis ofglandular epithe-
lial cells and inhibition ofapoptosis in infil-
trating lymphocytes (59). bcl-2 is a potent
downregulator ofapoptosis in many systems,
including peripheral blood of patients with
lupus. The sex hormonal modulation of
apoptosis through effects on bcl-2 is a fertile
field for future research uniting the three
important fields ofhormones, oncogenes,
and apoptosis.
Conclusions
The fact that various types of organ and
nonorgan-specific autoimmune diseases in
both humans and experimental animals occur
predominantly in females strongly implies
that gender plays a major role in the initiation
or progression of these disorders. Studies
from a number oflaboratories have clearly
shown that sex steroid hormones markedly
modulate many ofthese disorders. There is a
paucity ofinformation, however, that links
environmental estrogens (endocrine-disrupt-
ing chemicals) with autoimmune diseases. It
is conceivable that a subset of the human
population may be more susceptible to
autoimmune diseases (as opposed to the gen-
eral population). It is possible that suscepti-
bility to environmental chemical-induced
autoimmunity may vary with the genetic
background, gender, previous immune status,
age and duration ofexposure, and immune
status at the time of contact with these
agents. Chronic exposure (e.g., sustained low
dose) may have more adverse effects than
acute exposures. Although valuable data to
ascertain the linkage ofenvironmental agents
with autoimmune diseases in humans can be
obtained (e.g., performingsequential immuno-
logical studies in occupational or accidentally
exposed populations, or populations living
near contaminated sites), there are inherent
limitations in performing detailed mechanistic
studies in humans. Animal models can be
advantageously employed to study a number
ofthese aspects. For example, the availability
ofseveral strains ofgenetic-prone autoimmune
and nonautoimmune mice will elucidate the
response ofnormal and autoimmune individu-
als to a given chemical. Animal models will
also permit the performance ofstudies involv-
ing chronic or acute exposure ofchemicals
during fetal to adult stages oflife. Certain ages
oflife (e.g., fetal, neonatal, or senescent stages
oflife) may be more susceptible to environ-
mental chemical-induced autoimmunity.
Our studies and those ofothers show that
estrogens induce imbalances in T and B cells.
In general, estrogens bring about hypoactivity
ofT cell subsets and hyperactivity ofB cells
(3-5,32). This may form the underlying basis
for induction ofautoimmunity by estrogen.
Although estrogen induces hypoactivity of
T cells (as in the above experimental systems),
it is nevertheless likely that selected subsets of
T cells may be errant in functioning (e.g.,
overproducing certain cytokines or responding
aberrantly to T-cell activation signals).
Regulatory cells that hold in check auto-
reactive cells may be affected by hormones.
This could promote immune dysregulation
including autoimmunity.
It is important to recognize that the
effects ofsex hormones on the immune sys-
tem should not be generalized. To illustrate
this point, Sullivan (60) has shown that
androgens have a stimulatory effect on
mucosal immunity in the eye, no effect on
the uterus, and an inhibitory effect in the
mammary gland. The outcome of immune
responses is dependent upon highly complex
interactions ofsex hormones with several tis-
sues. Estrogen could have either a stimulatory
or suppressive effect on the immune system,
depending on dose and duration, the age of
the individual, local site, activation status of
the cells, availability ofcostimulatory signals,
or the expression ofreceptors. It should there-
fore not be surprising that environmental
estrogens may have the same or varied effects
on various autoimmune diseases. It is antici-
pated that much human and animal data will
become available in the near future to address
the precise association of environmental
agents and autoimmune diseases. Mechanistic
studies in animal models (or in humans) may
then prove to be very useful in understand-
ing the induction or advancement ofdisease,
and exploring new avenues to correct these
conditions therapeutically.
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